Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05896254
Registration number
NCT05896254
Ethics application status
Date submitted
31/05/2023
Date registered
9/06/2023
Date last updated
18/07/2024
Titles & IDs
Public title
Study of MAR001 in Adults With Metabolic Dysfunction
Query!
Scientific title
A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of MAR001 in Patients With Metabolic Dysfunction
Query!
Secondary ID [1]
0
0
MAR-102
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hypertriglyceridemia
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Other metabolic disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - MAR001
Treatment: Drugs - Placebo
Experimental: MAR001 - Subcutaneous injection
Placebo comparator: Placebo - Subcutaneous injection
Treatment: Drugs: MAR001
Subcutaneous injection
Treatment: Drugs: Placebo
Subcutaneous injection
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Safety and tolerability of MAR001
Query!
Assessment method [1]
0
0
Incidence and frequency of treatment-emergent adverse events
Query!
Timepoint [1]
0
0
12 weeks
Query!
Secondary outcome [1]
0
0
Effect of MAR001 on triglyceride metabolism
Query!
Assessment method [1]
0
0
Change from baseline in triglyceride levels
Query!
Timepoint [1]
0
0
12 weeks
Query!
Eligibility
Key inclusion criteria
* Willingness to provide informed consent and comply with the intervention
* Women of childbearing potential and men agreeing to use an appropriate method of contraception for the duration of the study
* Evidence of metabolic dysfunction at screening (triglyceride levels > 2.8 mmol/L)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Any condition which in the opinion of the investigator prevents the participant from complying with study procedures or prevents the participant from completing the study or interferes with the interpretation of study results
* Pregnant or breastfeeding mothers
* Terminal illness with expected survival of less than 1 year
Note: additional inclusion/exclusion criteria may apply, per protocol
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
22/07/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/11/2024
Query!
Actual
Query!
Sample size
Target
48
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Brisbane Site - Brisbane
Query!
Recruitment hospital [2]
0
0
Melbourne Site - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
4006 - Brisbane
Query!
Recruitment postcode(s) [2]
0
0
3004 - Melbourne
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Marea Therapeutics
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the safety and tolerability of multiple doses of MAR001in adult volunteers with metabolic dysfunction.
Query!
Trial website
https://clinicaltrials.gov/study/NCT05896254
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Alex DePaoli
Query!
Address
0
0
Marea Tx
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Jennifer Tam
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
415-766-3610
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT05896254
Download to PDF